Wei Wan, Li Guodong, Liu Zhaoheng, Yang Haojie, Liu Shuo, Zou Xinxin, Jiao Yang
Graduate School, Beijing University of Chinese Medicine, Beijing 100029, P.R. China.
Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100078, P.R. China.
Exp Ther Med. 2022 Jan;23(1):110. doi: 10.3892/etm.2021.11033. Epub 2021 Dec 2.
Feibi decoction (FBD) is a traditional Chinese herbal medicine and has been clinically used in the treatment of pulmonary fibrosis (PF), which is characterized by diffuse interstitial inflammation and exaggerated collagen accumulation. However, the potential mechanisms remain to be elucidated. The present study aimed to investigate the effect of FBD-medicated serum (FBDS) on lipopolysaccharide (LPS)-induced inflammation in macrophages. In RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs), FBDS treatment significantly inhibited the production of pro-inflammatory cytokines induced by LPS. In addition, it was indicated that FBDS treatment suppressed the activation of NF-κB and Smad2/Smad3 following LPS treatment. Furthermore, FBDS treatment decreased the expression of transforming growth factor-β1 and chitinase-3-like protein 1. In conclusion, the results demonstrated that treatment with FBDS inhibited LPS-induced inflammation in RAW264.7 and BMDM cells. These data may improve understanding of the effect of FBD on anti-inflammation and help determine the mechanisms underlying the alleviation of PF via FBD.
肺痹汤（FBD）是一种传统中药，已被临床用于治疗肺纤维化（PF），其特征为弥漫性间质性炎症和过度的胶原蛋白积累。然而，其潜在机制仍有待阐明。本研究旨在探讨肺痹汤含药血清（FBDS）对脂多糖（LPS）诱导的巨噬细胞炎症的影响。在RAW264.7巨噬细胞和骨髓来源的巨噬细胞（BMDM）中，FBDS处理显著抑制了LPS诱导的促炎细胞因子的产生。此外，结果表明FBDS处理抑制了LPS处理后NF-κB和Smad2/Smad3的激活。此外，FBDS处理降低了转化生长因子-β1和几丁质酶-3样蛋白1的表达。总之，结果表明FBDS处理可抑制RAW264.7和BMDM细胞中LPS诱导的炎症。这些数据可能有助于加深对肺痹汤抗炎作用的理解，并有助于确定肺痹汤缓解肺纤维化的潜在机制。
